

Minutes of Pre-bid meeting for Procurement of STI / RTI DRUG KITS against: IFB No. RITES/MSM/NACP/01/2015 held on 28/07/2015 at 14:00 hr at RITES office.

1. The following were present:-

I) From RITES

S/Shri

R K Sharma, DGM/MSM – In Chair

Manoj Kumar Das, Manger/MSM

B N Meena, AM/MSM

II) Firms which attended the pre bid conference are as follows:

S. No.	Name of representative S/Shri	Name of Firm
1	A Sharma	M/s Hospimax Healthcare Pvt. Ltd., New Delhi
2	Vishal Mahajan	M/s Micron Pharma, Delhi
3	Susheel Manchanda	M/s Manchanda Medicos
4	Sushil Sharma	M/s Verve Humancare Laboratories
5	M L Shah	M/s Hindustan Lab

M/s Aurochem Laboratories (I) Pvt. Ltd has submitted their queries through letter & email.

- Initiating the discussion, chairperson welcomed the participants. It was explained that purpose of Pre-bid meet is to educate the bidders regarding various important provisions of the bidding documents and also to clarify any queries that the bidders may have in the subject bidding documents.
- The issues raised during the pre bid meeting and clarifications are as under-

S. No.	Query Raised	Clarification
1.	<p>One of the prospective bidders has mentioned that they have been regularly quoting this tender for schedule II & IV and successfully completed contract within delivery period by supplying two lots.</p> <p>But in above tender same product has been instructed to supply in six lots in 22 months at 36 consignees i.e. 216 Supplies and Invoices, resulting into delay in collection of CRC /FAC and remittance by keeping record of LD.</p> <p>Delivery Schedule & Consignee details on page no 57: (i) 1st Lot of 14% quantity within 90 days of NOA, (ii) 2nd Lot of 14% quantity between 91 to 180 days of NOA and (iii) 3rd Lot of 19% quantity between 181 to 270 days of NOA, (iv) 4th Lot of 16% quantity within 361 to 450 days of NOA, (v) 5th Lot of 16% quantity between 451 to 540 days of NOA and (vi) 6th Lot of balance 21% quantity between 541 to 630 days of NOA)</p> <p>The firm has requested that, as Nos. of cartoons and storage place required in this orders is merely negligible compare to storage facility available with all SACS of each state of India. It is requested to kindly permit us to supply said NOA within Two Lots in 12 months i.e 50% within 90 days to 120 days and 50% within 300 days to 360 days with applicable LD and convenience for the supplier to Manufacture minimum batch size, test report,</p>	<p>Delivery Schedule for schedule II & IV has been revised as mentioned below:</p> <p>Delivery Schedule For Schedule II:</p> <p>(i) 1st Lot quantity within 90 days of NOA, (ii) 2nd Lot quantity between 181 to 270 days of NOA and (iii) 3rd Lot quantity between 361 to 450 days of NOA, (iv) 4th Lot quantity within 451 to 540 days of NOA,</p> <p>Delivery Schedule For Schedule IV:</p> <p>(i) 1st Lot quantity within 90 days of NOA, (ii) 2nd Lot quantity between 300 to 360 days of NOA</p> <p>Please refer Amendment No.1</p>

S. No.	Query Raised	Clarification
	collect CRC and FAC with pairing and issue necessary amendment in delivery schedule.	
2.	Is manufacturing license required for kits or individual items	The manufacturing license is essential for individual drug. Arranging any permission/ license required from the regulator for supply in kit form will be the responsibility of the supplier.
3.	<p>One of the prospective bidders has mentioned that as per clause ITB 6.1.1(C): Manufacturing & Marketing Experience Certificate:- According to the tender "the bidder must have at least two years of manufacturing and marketing experience of the Particular items as a manufacturer for each regulated Product quoted in the Tender".</p> <p>Please have a look on the Terms of previous tender in which it was mentioned that the bidder must have at least One year of manufacturing and marketing experience of the Particular items as a manufacturer for each regulated Product quoted in the Tender.</p> <p>The firm has requested to kindly amend the above clause as "the bidder must have at least two years of manufacturing and marketing experience of the similar items and for the particular/ specific items should be manufactured by the firm ones in any of last three previous years by the firm and should have manufacturing license for the specific drug.</p>	The is no change in the existing clause
4.	Manufacturing & selling Experience of specific Products (clause ITB 6.1.1(C)): We request you to consider the manufacturing & selling Experience of quoted Products in "unit wise manufacturing & selling basis" instead of Kits/ combination of Products because you are the only Organization which intends to buy these products in Kits.	This clause is for manufacturing and marketing experience of particular items. Therefore if the bidder has experience of each item of a kit separately then they will meet this requirement.
5.	<p>(i) Performance Bank Guarantee (PBG) (GCC 8): We request you to kindly consider the PBG schedule wise i.e. You may ask for PBG for 1st three Lots in first phase & remaining three Lots in second phase.</p> <p>(ii) Performance Bank Guarantee (PBG) (GCC 8): Please accept PBG lot wise as all the lots are being completed in almost 02 years & it will be burden for submitting PBG of longer period as it will not solve the purpose because the shelf life of the item will be expiring after 36 months.</p>	<p>Requirement of Performance Bank Guarantee has been revised as mentioned below:</p> <p>Performance security can be submitted in two parts -50% each. The first part will be released after completion of warranty obligation of first 3 lots for Schedule I, III, V to VIII and first 2 Lots for Schedule II and first Lot for Schedule IV.</p> <p>Please refer Amendment No.1</p>
6.	For Non Manufacturer Bidder that it has successfully completed at least one (1) contract for similar goods within the period of last five years (preceding two months before the date of bid opening) for supply of goods. Minimum value of completed contract for each schedule should be as per Appendix „A“ and that include comparable products e.g. drugs/ pharmaceuticals (Capsule/Tablet/Vial/Syringes). Bidder shall submit list	Similar products are as defined in Appendix 'A'.

S. No.	Query Raised	Clarification
	<p>of major supply contracts conducted within the last five years as per form 6 (Proforma for Performance Statement) in Section V.</p> <p>Please clarify that in Qualification Criteria you had mentioned Comparable products e.g. (Capsules/Tablets/Vial/Syringes) & in Appendix A you are only mentioning Tablets/Capsules.</p> <p>We request you to accept experience of supply of Health sector goods for Non manufacturer bidders that includes syringes & other medical consumables.</p>	
7.	<p>Against ITB clause (e)(i) regarding successfully completed at least one contract: Hospital/ Department approves rates for one year & keep on placing small orders depending on their monthly/bimonthly requirement, the value of the orders executed in one year should be considered as one contract which has been accepted in the tenders floated by MOH&FW.</p> <p>Please accept the quantity & value of the pharmaceuticals executed before two months of the date of opening of the bid.</p>	<p>Rate contracts cannot be accepted as one executed contract. However, any single contract against Rate contract which qualifies the requirement of bid document can be accepted.</p> <p>Partly executed contract cannot be considered for the purpose of this clause.</p>
8.	<p>Govt of India is contemplating GST with effect from 01.04.2015 in lieu of Excise duty+ central vat+ other taxes etc. At present ED is 6% & Central VAT is 5%, if GST is equal to 11% then no amendment is required. If GST is more than existing rate, the same should be applicable to this tender, if it is less than 11% the same will be reduced by the bidder.</p> <p>It is requested to incorporate a clause on above issue.</p>	<p>The below clause may be incorporated in the bid document:</p> <p>If GST is implemented by Govt. of India during the currency of the contract then applicable rates of GST will be reimbursed in place of existing taxes and duties against documentary evidence.</p>

Meeting concluded with thanks to the participants for their active participation.